This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Genvara Biopharma, Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations by Michael Bristow in Atrial Fibrillation Treatment.
Introduction
Michael Bristow is an accomplished inventor based in Englewood, Colorado. He has made significant contributions to the field of medicine, particularly in the treatment of atrial fibrillation. His innovative work focuses on the use of bucindolol, a beta-blocker, for patients with specific genetic markers.
Latest Patents
Michael Bristow holds a patent for "Methods and compositions involving bucindolol for the treatment of atrial fibrillation." This patent addresses the treatment of atrial fibrillation in patients who are homozygous Arg389 in the β-adrenergic receptor gene, including those with heart failure. The patent represents a significant advancement in personalized medicine.
Career Highlights
Michael Bristow is currently associated with Genvara Biopharma, Inc., where he continues to develop innovative treatments. His work has been instrumental in advancing therapeutic options for patients suffering from atrial fibrillation.
Collaborations
Michael collaborates with Christopher Dufton, contributing to the research and development efforts at Genvara Biopharma, Inc. Their partnership enhances the potential for breakthroughs in the treatment of cardiovascular conditions.
Conclusion
Michael Bristow's contributions to the field of atrial fibrillation treatment through his patent and work at Genvara Biopharma, Inc. highlight the importance of innovation in medicine. His efforts pave the way for improved patient outcomes and personalized treatment strategies.